United Parcel Service, Inc. (NYSE:UPS) is a package delivery and logistics provider ... Despite the challenges related to the EYLEA product line, the analyst views potential in Regeneron ...

EBITDA before special items decreases to 4.085 billion euros (minus 7.4 percent) / Moderate decline in sales (Fx & p adj.) at ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

Total revenues decreased 4% year over year to $3 billion due to lower sales of lead drug Eylea. Revenues also missed the Zacks Consensus Estimate of $3.27 billion. Sales of oncology drug ...

In both trials, patients were randomized into 3 treatment groups to receive either: EYLEA HD every 3 months, EYLEA HD every 4 months, or EYLEA every 2 months. The lead sponsors of the trials were ...

CEO Leonard Schleifer specifically cited a funding gap at patient assistance foundations as a catalyst for more patients and physicians turning to off-label Avastin over EYLEA, resulting in a ...

Meanwhile, its high-dose version, known as Eylea HD, brought in $453M, with over a twofold rise from the prior year period. Meanwhile, REGN’s asthma drug Dupixent, marketed with Sanofi (SNY ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the presentation of 27 abstracts, including eight oral sessions, featuring EYLEA HD (aflibercept) Injection 8 mg at the upcoming ARVO ...

Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...